| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatitis | 100 | 2026 | 108 | 21.210 |
Why?
|
| Pancreatic Neoplasms | 93 | 2026 | 100 | 19.540 |
Why?
|
| Pancreatitis, Chronic | 67 | 2026 | 69 | 14.510 |
Why?
|
| Pancreas | 125 | 2025 | 144 | 14.200 |
Why?
|
| Carcinoma, Pancreatic Ductal | 37 | 2025 | 41 | 9.050 |
Why?
|
| Pancreatitis, Alcoholic | 26 | 2026 | 28 | 7.340 |
Why?
|
| Humans | 256 | 2026 | 6794 | 6.440 |
Why?
|
| Animals | 186 | 2026 | 1875 | 6.070 |
Why?
|
| Diabetes Mellitus | 25 | 2026 | 208 | 5.280 |
Why?
|
| Ethanol | 30 | 2025 | 86 | 4.870 |
Why?
|
| Pancreas, Exocrine | 19 | 2025 | 19 | 4.850 |
Why?
|
| Apoptosis | 39 | 2024 | 179 | 3.840 |
Why?
|
| Acute Disease | 55 | 2026 | 91 | 3.670 |
Why?
|
| Calcium | 49 | 2022 | 117 | 3.630 |
Why?
|
| Mice | 72 | 2026 | 746 | 3.440 |
Why?
|
| Male | 125 | 2026 | 3671 | 3.400 |
Why?
|
| Pancreatic Stellate Cells | 13 | 2024 | 13 | 3.230 |
Why?
|
| Disease Models, Animal | 42 | 2024 | 231 | 3.050 |
Why?
|
| Alcohol Drinking | 11 | 2025 | 65 | 2.980 |
Why?
|
| Signal Transduction | 35 | 2025 | 246 | 2.730 |
Why?
|
| Rats | 79 | 2024 | 571 | 2.640 |
Why?
|
| Acinar Cells | 17 | 2025 | 17 | 2.520 |
Why?
|
| Female | 81 | 2026 | 4060 | 2.330 |
Why?
|
| Adaptor Proteins, Signal Transducing | 6 | 2025 | 19 | 2.310 |
Why?
|
| Adenocarcinoma | 13 | 2024 | 50 | 2.300 |
Why?
|
| NF-kappa B | 24 | 2022 | 56 | 2.270 |
Why?
|
| Ceruletide | 29 | 2022 | 29 | 2.270 |
Why?
|
| Pancreatic Diseases | 9 | 2024 | 11 | 2.240 |
Why?
|
| Smoking | 14 | 2026 | 86 | 2.060 |
Why?
|
| Alcoholism | 6 | 2022 | 25 | 2.040 |
Why?
|
| Protein Kinase C | 18 | 2022 | 31 | 2.020 |
Why?
|
| Macrophages | 13 | 2025 | 40 | 1.980 |
Why?
|
| Liver Neoplasms | 8 | 2025 | 63 | 1.980 |
Why?
|
| Biomedical Research | 12 | 2026 | 34 | 1.940 |
Why?
|
| Middle Aged | 58 | 2026 | 2108 | 1.900 |
Why?
|
| Risk Factors | 38 | 2026 | 767 | 1.820 |
Why?
|
| Simvastatin | 6 | 2024 | 8 | 1.810 |
Why?
|
| Islets of Langerhans | 6 | 2023 | 11 | 1.770 |
Why?
|
| Aged | 49 | 2026 | 1539 | 1.770 |
Why?
|
| Autophagy | 14 | 2024 | 29 | 1.760 |
Why?
|
| Cell Proliferation | 18 | 2025 | 143 | 1.740 |
Why?
|
| Adult | 51 | 2026 | 2113 | 1.720 |
Why?
|
| Tumor Microenvironment | 10 | 2025 | 25 | 1.710 |
Why?
|
| Severity of Illness Index | 16 | 2026 | 118 | 1.710 |
Why?
|
| Transcription Factors | 7 | 2025 | 53 | 1.700 |
Why?
|
| Neoplasms | 3 | 2024 | 92 | 1.690 |
Why?
|
| Diabetes Mellitus, Type 2 | 14 | 2024 | 279 | 1.690 |
Why?
|
| Biomarkers, Tumor | 11 | 2025 | 51 | 1.620 |
Why?
|
| Histone Deacetylases | 4 | 2025 | 5 | 1.600 |
Why?
|
| Cholecystokinin | 15 | 2010 | 18 | 1.570 |
Why?
|
| Cells, Cultured | 27 | 2022 | 234 | 1.480 |
Why?
|
| Endoplasmic Reticulum | 12 | 2020 | 21 | 1.440 |
Why?
|
| United States | 32 | 2026 | 1019 | 1.400 |
Why?
|
| Fibrosis | 15 | 2024 | 53 | 1.400 |
Why?
|
| Necrosis | 14 | 2022 | 30 | 1.360 |
Why?
|
| Rats, Sprague-Dawley | 35 | 2019 | 282 | 1.350 |
Why?
|
| Cell Line, Tumor | 26 | 2025 | 156 | 1.330 |
Why?
|
| Biomarkers | 16 | 2026 | 214 | 1.280 |
Why?
|
| Pancreatitis, Acute Necrotizing | 10 | 2019 | 10 | 1.260 |
Why?
|
| Early Detection of Cancer | 8 | 2025 | 59 | 1.260 |
Why?
|
| Unfolded Protein Response | 8 | 2020 | 10 | 1.230 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2020 | 4 | 1.220 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2022 | 24 | 1.220 |
Why?
|
| Gene Deletion | 4 | 2024 | 17 | 1.210 |
Why?
|
| Sincalide | 32 | 2014 | 35 | 1.150 |
Why?
|
| Mice, Inbred C57BL | 21 | 2025 | 258 | 1.140 |
Why?
|
| Caspases | 13 | 2009 | 29 | 1.120 |
Why?
|
| Prospective Studies | 25 | 2026 | 331 | 1.120 |
Why?
|
| Repressor Proteins | 3 | 2025 | 13 | 1.110 |
Why?
|
| Mitochondria | 13 | 2026 | 37 | 1.100 |
Why?
|
| Trans-Activators | 3 | 2025 | 10 | 1.090 |
Why?
|
| Antineoplastic Agents | 7 | 2020 | 72 | 1.060 |
Why?
|
| Stress, Physiological | 4 | 2011 | 19 | 1.050 |
Why?
|
| Aging | 2 | 2025 | 105 | 1.030 |
Why?
|
| Pharmaceutical Preparations | 4 | 2018 | 11 | 1.010 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2016 | 19 | 0.980 |
Why?
|
| Prognosis | 16 | 2024 | 220 | 0.980 |
Why?
|
| Quality of Life | 10 | 2026 | 184 | 0.980 |
Why?
|
| Amylases | 28 | 2010 | 28 | 0.970 |
Why?
|
| Cell Membrane | 15 | 2016 | 54 | 0.970 |
Why?
|
| Abdominal Pain | 8 | 2026 | 15 | 0.960 |
Why?
|
| Cigarette Smoking | 4 | 2025 | 20 | 0.950 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2025 | 2 | 0.940 |
Why?
|
| Mice, Knockout | 18 | 2025 | 150 | 0.920 |
Why?
|
| Blood Proteins | 2 | 2025 | 4 | 0.920 |
Why?
|
| Membrane Proteins | 6 | 2025 | 48 | 0.910 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 12 | 2026 | 12 | 0.910 |
Why?
|
| Lysosomes | 5 | 2024 | 14 | 0.910 |
Why?
|
| MicroRNAs | 5 | 2025 | 54 | 0.910 |
Why?
|
| Cell-Derived Microparticles | 1 | 2025 | 1 | 0.900 |
Why?
|
| Cytokines | 13 | 2024 | 80 | 0.880 |
Why?
|
| ORAI1 Protein | 3 | 2024 | 3 | 0.870 |
Why?
|
| Trypsin | 11 | 2022 | 14 | 0.860 |
Why?
|
| Reactive Oxygen Species | 9 | 2024 | 45 | 0.860 |
Why?
|
| Carbachol | 25 | 2010 | 25 | 0.850 |
Why?
|
| Recurrence | 11 | 2026 | 55 | 0.850 |
Why?
|
| RNA, Messenger | 17 | 2022 | 190 | 0.830 |
Why?
|
| NADPH Oxidases | 7 | 2013 | 14 | 0.820 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 6 | 2022 | 24 | 0.810 |
Why?
|
| Liver Cirrhosis | 4 | 2024 | 58 | 0.810 |
Why?
|
| Insulin | 7 | 2024 | 146 | 0.810 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 3 | 2022 | 10 | 0.810 |
Why?
|
| Protein Kinase C-epsilon | 4 | 2014 | 5 | 0.800 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 6 | 2024 | 35 | 0.790 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2024 | 64 | 0.770 |
Why?
|
| Apoptosis Regulatory Proteins | 6 | 2019 | 17 | 0.760 |
Why?
|
| Cell Death | 11 | 2023 | 20 | 0.750 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2025 | 88 | 0.750 |
Why?
|
| Secondary Prevention | 1 | 2022 | 16 | 0.720 |
Why?
|
| Enzyme Inhibitors | 14 | 2009 | 53 | 0.700 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2017 | 48 | 0.700 |
Why?
|
| Inflammation Mediators | 3 | 2019 | 30 | 0.690 |
Why?
|
| Endoplasmic Reticulum Stress | 3 | 2020 | 10 | 0.690 |
Why?
|
| Smoke | 4 | 2017 | 6 | 0.690 |
Why?
|
| Cell Movement | 6 | 2025 | 38 | 0.680 |
Why?
|
| Organelles | 2 | 2019 | 4 | 0.680 |
Why?
|
| Up-Regulation | 5 | 2021 | 94 | 0.670 |
Why?
|
| Pain Management | 4 | 2026 | 27 | 0.670 |
Why?
|
| Extracellular Vesicles | 3 | 2026 | 6 | 0.660 |
Why?
|
| Disease Management | 2 | 2019 | 33 | 0.650 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 170 | 0.650 |
Why?
|
| Sex Characteristics | 1 | 2021 | 39 | 0.650 |
Why?
|
| Colorectal Neoplasms | 3 | 2025 | 23 | 0.650 |
Why?
|
| Inflammation | 9 | 2022 | 143 | 0.640 |
Why?
|
| Phosphatidylinositol 3-Kinases | 6 | 2024 | 19 | 0.640 |
Why?
|
| Progressive Patient Care | 1 | 2019 | 1 | 0.630 |
Why?
|
| Chronic Pain | 3 | 2026 | 12 | 0.630 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2021 | 19 | 0.620 |
Why?
|
| Extracellular Matrix | 7 | 2024 | 22 | 0.620 |
Why?
|
| Phagosomes | 1 | 2019 | 2 | 0.610 |
Why?
|
| Incidence | 15 | 2024 | 197 | 0.610 |
Why?
|
| Amidines | 1 | 2019 | 1 | 0.610 |
Why?
|
| Proline | 1 | 2019 | 5 | 0.610 |
Why?
|
| Calcium Channel Blockers | 1 | 2019 | 8 | 0.610 |
Why?
|
| Mutation | 6 | 2022 | 97 | 0.600 |
Why?
|
| Carcinoma in Situ | 2 | 2016 | 3 | 0.600 |
Why?
|
| Anticholesteremic Agents | 1 | 2019 | 21 | 0.600 |
Why?
|
| Neutrophils | 7 | 2023 | 14 | 0.590 |
Why?
|
| Immunity, Innate | 4 | 2021 | 20 | 0.590 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 28 | 0.590 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 2024 | 52 | 0.580 |
Why?
|
| Trypsinogen | 7 | 2022 | 9 | 0.580 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2018 | 1 | 0.570 |
Why?
|
| Cell Culture Techniques | 2 | 2017 | 18 | 0.570 |
Why?
|
| Protein Kinase C-delta | 6 | 2009 | 7 | 0.560 |
Why?
|
| Calcium-Transporting ATPases | 5 | 2004 | 6 | 0.550 |
Why?
|
| Case-Control Studies | 10 | 2026 | 108 | 0.550 |
Why?
|
| Central Nervous System Depressants | 5 | 2007 | 14 | 0.540 |
Why?
|
| Retrospective Studies | 13 | 2024 | 681 | 0.530 |
Why?
|
| Cyclic GMP | 8 | 1997 | 22 | 0.520 |
Why?
|
| bcl-X Protein | 5 | 2013 | 5 | 0.520 |
Why?
|
| Hepatocytes | 1 | 2017 | 85 | 0.510 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2026 | 26 | 0.510 |
Why?
|
| Cadherins | 1 | 2016 | 4 | 0.510 |
Why?
|
| Hospitalization | 4 | 2026 | 128 | 0.510 |
Why?
|
| Time Factors | 15 | 2026 | 321 | 0.510 |
Why?
|
| Glucose | 1 | 2016 | 50 | 0.490 |
Why?
|
| Diet | 5 | 2026 | 111 | 0.490 |
Why?
|
| Ellagic Acid | 2 | 2013 | 2 | 0.480 |
Why?
|
| Fibroblasts | 3 | 2007 | 53 | 0.480 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2013 | 155 | 0.480 |
Why?
|
| Societies, Medical | 3 | 2015 | 67 | 0.480 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2013 | 6 | 0.480 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2016 | 1 | 0.480 |
Why?
|
| Artificial Intelligence | 5 | 2022 | 31 | 0.470 |
Why?
|
| Fatty Liver | 4 | 2025 | 59 | 0.470 |
Why?
|
| Risk Assessment | 9 | 2026 | 197 | 0.470 |
Why?
|
| Blotting, Western | 11 | 2019 | 110 | 0.460 |
Why?
|
| Specimen Handling | 3 | 2021 | 6 | 0.460 |
Why?
|
| Obesity | 6 | 2023 | 226 | 0.460 |
Why?
|
| Rats, Wistar | 12 | 2017 | 55 | 0.460 |
Why?
|
| Gene Expression Regulation | 5 | 2019 | 120 | 0.450 |
Why?
|
| Length of Stay | 4 | 2024 | 53 | 0.450 |
Why?
|
| Multiple Organ Failure | 3 | 2021 | 8 | 0.450 |
Why?
|
| Kidney Neoplasms | 3 | 2024 | 12 | 0.440 |
Why?
|
| Gastroenterology | 1 | 2014 | 2 | 0.440 |
Why?
|
| In Vitro Techniques | 21 | 2009 | 72 | 0.440 |
Why?
|
| Homeostasis | 4 | 2024 | 40 | 0.430 |
Why?
|
| Cell Line | 12 | 2021 | 124 | 0.420 |
Why?
|
| Cross-Sectional Studies | 10 | 2026 | 506 | 0.420 |
Why?
|
| Benzoquinones | 1 | 2013 | 4 | 0.410 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2024 | 63 | 0.410 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2024 | 10 | 0.410 |
Why?
|
| Caspase 3 | 9 | 2010 | 27 | 0.410 |
Why?
|
| Proteomics | 3 | 2025 | 9 | 0.410 |
Why?
|
| Mice, Inbred BALB C | 8 | 2021 | 46 | 0.410 |
Why?
|
| Bile Acids and Salts | 4 | 2014 | 12 | 0.400 |
Why?
|
| Enterovirus B, Human | 2 | 2026 | 2 | 0.400 |
Why?
|
| Enzyme Activation | 12 | 2016 | 39 | 0.400 |
Why?
|
| Phosphorylation | 8 | 2016 | 73 | 0.400 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2024 | 6 | 0.390 |
Why?
|
| Delphi Technique | 3 | 2024 | 16 | 0.390 |
Why?
|
| Disease Progression | 9 | 2023 | 170 | 0.390 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 3 | 2010 | 3 | 0.390 |
Why?
|
| Intestinal Mucosa | 3 | 2024 | 17 | 0.380 |
Why?
|
| Coculture Techniques | 4 | 2022 | 9 | 0.370 |
Why?
|
| Kinetics | 20 | 2002 | 69 | 0.360 |
Why?
|
| Body Mass Index | 2 | 2024 | 145 | 0.360 |
Why?
|
| Aged, 80 and over | 11 | 2024 | 497 | 0.360 |
Why?
|
| Feeding Behavior | 2 | 2026 | 38 | 0.360 |
Why?
|
| Cohort Studies | 7 | 2024 | 285 | 0.360 |
Why?
|
| Digestion | 2 | 2008 | 2 | 0.360 |
Why?
|
| Cytosol | 13 | 2007 | 26 | 0.350 |
Why?
|
| Models, Biological | 9 | 2020 | 64 | 0.350 |
Why?
|
| Stromal Cells | 4 | 2024 | 10 | 0.350 |
Why?
|
| Chemokines | 8 | 2024 | 11 | 0.350 |
Why?
|
| Oxidative Stress | 6 | 2024 | 102 | 0.350 |
Why?
|
| Analgesics, Opioid | 2 | 2025 | 58 | 0.340 |
Why?
|
| Exosomes | 2 | 2025 | 7 | 0.340 |
Why?
|
| Guinea Pigs | 19 | 1995 | 20 | 0.340 |
Why?
|
| Transcription Factor AP-1 | 5 | 2003 | 7 | 0.340 |
Why?
|
| Prostatic Neoplasms | 3 | 2020 | 45 | 0.330 |
Why?
|
| Acetylcholinesterase | 1 | 2010 | 1 | 0.330 |
Why?
|
| Receptor, Muscarinic M3 | 1 | 2010 | 1 | 0.330 |
Why?
|
| Receptor, Muscarinic M1 | 1 | 2010 | 1 | 0.330 |
Why?
|
| Cholinergic Agents | 1 | 2010 | 2 | 0.330 |
Why?
|
| Research Design | 3 | 2021 | 41 | 0.330 |
Why?
|
| Peptide Fragments | 2 | 2009 | 23 | 0.330 |
Why?
|
| Calcium Signaling | 3 | 2020 | 9 | 0.330 |
Why?
|
| Fatty Acids | 4 | 2024 | 25 | 0.320 |
Why?
|
| Folic Acid | 1 | 2010 | 3 | 0.320 |
Why?
|
| Pancreatic Juice | 4 | 2021 | 4 | 0.320 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2020 | 13 | 0.320 |
Why?
|
| Fibroma, Desmoplastic | 1 | 2009 | 1 | 0.310 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 29 | 0.310 |
Why?
|
| Diet, High-Fat | 4 | 2017 | 59 | 0.300 |
Why?
|
| Interleukin-6 | 5 | 2024 | 45 | 0.300 |
Why?
|
| Guanylate Cyclase | 4 | 2000 | 4 | 0.300 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 3 | 2024 | 8 | 0.300 |
Why?
|
| Recovery of Function | 2 | 2021 | 11 | 0.290 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2006 | 7 | 0.290 |
Why?
|
| Collagen | 4 | 2022 | 31 | 0.290 |
Why?
|
| Cholinergic Agonists | 1 | 2008 | 1 | 0.290 |
Why?
|
| Protein Kinases | 1 | 2008 | 5 | 0.290 |
Why?
|
| Follow-Up Studies | 6 | 2026 | 268 | 0.290 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 4 | 2026 | 4 | 0.290 |
Why?
|
| Fibronectins | 6 | 2016 | 18 | 0.290 |
Why?
|
| Gastrointestinal Tract | 1 | 2008 | 6 | 0.290 |
Why?
|
| Sensitivity and Specificity | 6 | 2024 | 98 | 0.290 |
Why?
|
| Methionine Adenosyltransferase | 2 | 2025 | 8 | 0.290 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 73 | 0.280 |
Why?
|
| Tetradecanoylphorbol Acetate | 10 | 1993 | 13 | 0.280 |
Why?
|
| Neoplasm Proteins | 3 | 2025 | 18 | 0.280 |
Why?
|
| Child | 3 | 2026 | 524 | 0.280 |
Why?
|
| Eating | 1 | 2008 | 31 | 0.280 |
Why?
|
| Coxsackievirus Infections | 2 | 2026 | 2 | 0.280 |
Why?
|
| Hyaluronic Acid | 3 | 2025 | 13 | 0.280 |
Why?
|
| Cell Survival | 9 | 2021 | 33 | 0.270 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 17 | 0.270 |
Why?
|
| Pancreatic Ducts | 6 | 2022 | 6 | 0.270 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2026 | 6 | 0.270 |
Why?
|
| Matrix Metalloproteinase 9 | 4 | 2017 | 7 | 0.270 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2007 | 3 | 0.270 |
Why?
|
| Deoxycytidine | 2 | 2018 | 3 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2013 | 27 | 0.270 |
Why?
|
| Mice, Nude | 6 | 2024 | 41 | 0.260 |
Why?
|
| TRPV Cation Channels | 3 | 2026 | 7 | 0.260 |
Why?
|
| Liver | 5 | 2014 | 157 | 0.250 |
Why?
|
| Protein Biosynthesis | 3 | 1997 | 9 | 0.250 |
Why?
|
| Immunohistochemistry | 8 | 2019 | 118 | 0.250 |
Why?
|
| Insulin-Secreting Cells | 2 | 2025 | 4 | 0.250 |
Why?
|
| Plasminogen | 1 | 2006 | 1 | 0.250 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2024 | 4 | 0.250 |
Why?
|
| Stomach Neoplasms | 2 | 2024 | 11 | 0.250 |
Why?
|
| Chronic Disease | 4 | 2019 | 167 | 0.250 |
Why?
|
| Cytochrome c Group | 3 | 2003 | 6 | 0.240 |
Why?
|
| Metagenomics | 1 | 2026 | 3 | 0.240 |
Why?
|
| Cytochromes c | 5 | 2014 | 7 | 0.240 |
Why?
|
| Machine Learning | 1 | 2026 | 12 | 0.240 |
Why?
|
| Capsaicin | 1 | 2026 | 2 | 0.240 |
Why?
|
| Enteral Nutrition | 2 | 2021 | 13 | 0.240 |
Why?
|
| Colitis | 2 | 2024 | 4 | 0.240 |
Why?
|
| Calcimycin | 12 | 1991 | 15 | 0.240 |
Why?
|
| Benzopyrans | 3 | 2010 | 3 | 0.240 |
Why?
|
| Bombesin | 10 | 1997 | 10 | 0.240 |
Why?
|
| Registries | 3 | 2023 | 63 | 0.240 |
Why?
|
| Adenosine Triphosphate | 5 | 2022 | 17 | 0.230 |
Why?
|
| Young Adult | 6 | 2026 | 567 | 0.230 |
Why?
|
| Predictive Value of Tests | 5 | 2026 | 127 | 0.230 |
Why?
|
| Ion Channels | 2 | 2020 | 14 | 0.230 |
Why?
|
| Phosphates | 2 | 2024 | 13 | 0.230 |
Why?
|
| Marijuana Use | 1 | 2025 | 9 | 0.230 |
Why?
|
| Lipase | 7 | 2010 | 10 | 0.230 |
Why?
|
| Marijuana Smoking | 1 | 2025 | 8 | 0.230 |
Why?
|
| Proteolysis | 3 | 2024 | 5 | 0.230 |
Why?
|
| Bioengineering | 1 | 2025 | 1 | 0.230 |
Why?
|
| Filtration | 1 | 2025 | 2 | 0.230 |
Why?
|
| Adsorption | 1 | 2025 | 2 | 0.230 |
Why?
|
| Cell Cycle Proteins | 2 | 2021 | 22 | 0.230 |
Why?
|
| Exocrine Pancreatic Insufficiency | 2 | 2026 | 2 | 0.230 |
Why?
|
| Thapsigargin | 5 | 2006 | 8 | 0.230 |
Why?
|
| Peptides | 3 | 2015 | 19 | 0.220 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2025 | 4 | 0.220 |
Why?
|
| Actins | 6 | 2016 | 28 | 0.220 |
Why?
|
| Pancreatic Cyst | 2 | 2021 | 2 | 0.220 |
Why?
|
| Secretory Vesicles | 2 | 2019 | 2 | 0.220 |
Why?
|
| California | 4 | 2019 | 230 | 0.220 |
Why?
|
| Enzyme Precursors | 3 | 2008 | 6 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 57 | 0.220 |
Why?
|
| Endocannabinoids | 1 | 2024 | 4 | 0.220 |
Why?
|
| Tissue Culture Techniques | 2 | 2017 | 5 | 0.220 |
Why?
|
| Age of Onset | 1 | 2024 | 16 | 0.220 |
Why?
|
| Esophageal Neoplasms | 1 | 2024 | 10 | 0.220 |
Why?
|
| Ghrelin | 1 | 2024 | 4 | 0.220 |
Why?
|
| Ascites | 1 | 2024 | 1 | 0.220 |
Why?
|
| Carcinogens | 3 | 2013 | 11 | 0.220 |
Why?
|
| Fluid Therapy | 2 | 2021 | 10 | 0.210 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2024 | 11 | 0.210 |
Why?
|
| Hypophosphatemia | 1 | 2024 | 5 | 0.210 |
Why?
|
| Lipocalin-2 | 1 | 2024 | 1 | 0.210 |
Why?
|
| Germ-Line Mutation | 1 | 2024 | 28 | 0.210 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2024 | 3 | 0.210 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2024 | 5 | 0.210 |
Why?
|
| Nanoparticles | 1 | 2024 | 6 | 0.210 |
Why?
|
| Genetic Testing | 1 | 2024 | 50 | 0.210 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2024 | 2 | 0.210 |
Why?
|
| Lipid Peroxidation | 1 | 2024 | 11 | 0.210 |
Why?
|
| Dinoprostone | 2 | 2022 | 6 | 0.210 |
Why?
|
| Global Burden of Disease | 1 | 2023 | 6 | 0.210 |
Why?
|
| Cross-Over Studies | 4 | 2025 | 27 | 0.210 |
Why?
|
| Drug Resistance | 1 | 2024 | 16 | 0.210 |
Why?
|
| Proteins | 3 | 2021 | 41 | 0.210 |
Why?
|
| DNA-Binding Proteins | 3 | 2011 | 38 | 0.210 |
Why?
|
| Acute Lung Injury | 1 | 2023 | 4 | 0.210 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2023 | 1 | 0.210 |
Why?
|
| Diagnostic Imaging | 2 | 2022 | 7 | 0.200 |
Why?
|
| Pain | 4 | 2024 | 38 | 0.200 |
Why?
|
| Drug Synergism | 4 | 2013 | 26 | 0.200 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2024 | 12 | 0.200 |
Why?
|
| Pancreatic Function Tests | 2 | 2021 | 3 | 0.200 |
Why?
|
| Neuralgia | 1 | 2023 | 5 | 0.200 |
Why?
|
| Nociceptive Pain | 1 | 2023 | 4 | 0.200 |
Why?
|
| Body Weight | 2 | 2021 | 90 | 0.200 |
Why?
|
| Smoking Cessation | 1 | 2023 | 25 | 0.200 |
Why?
|
| Myeloid Cells | 2 | 2024 | 4 | 0.200 |
Why?
|
| Cell Communication | 4 | 2020 | 11 | 0.200 |
Why?
|
| Clinical Trials as Topic | 5 | 2024 | 54 | 0.200 |
Why?
|
| Dietary Fats | 2 | 2021 | 19 | 0.200 |
Why?
|
| Hepatic Stellate Cells | 3 | 2025 | 37 | 0.200 |
Why?
|
| Cytoskeleton | 3 | 2002 | 4 | 0.200 |
Why?
|
| Caspase 8 | 4 | 2009 | 7 | 0.200 |
Why?
|
| Pancreatic Elastase | 3 | 1999 | 3 | 0.200 |
Why?
|
| Drainage | 2 | 2019 | 10 | 0.200 |
Why?
|
| Cholangitis | 1 | 2022 | 4 | 0.190 |
Why?
|
| Curcumin | 1 | 2003 | 8 | 0.190 |
Why?
|
| Bone Marrow | 1 | 2022 | 4 | 0.190 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2016 | 4 | 0.190 |
Why?
|
| Ultrasonography, Interventional | 1 | 2023 | 17 | 0.190 |
Why?
|
| MCF-7 Cells | 1 | 2022 | 15 | 0.190 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 25 | 0.190 |
Why?
|
| S-Adenosylmethionine | 1 | 2002 | 17 | 0.190 |
Why?
|
| Digestive System Abnormalities | 1 | 2022 | 1 | 0.190 |
Why?
|
| Superoxides | 2 | 2019 | 4 | 0.190 |
Why?
|
| Mass Screening | 2 | 2020 | 116 | 0.190 |
Why?
|
| Surveys and Questionnaires | 4 | 2026 | 280 | 0.190 |
Why?
|
| Chlorophyllides | 1 | 2022 | 1 | 0.190 |
Why?
|
| Multicenter Studies as Topic | 4 | 2026 | 15 | 0.190 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 3 | 2014 | 4 | 0.190 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2019 | 24 | 0.190 |
Why?
|
| Flavonoids | 1 | 2002 | 6 | 0.190 |
Why?
|
| Phenols | 1 | 2002 | 9 | 0.180 |
Why?
|
| Polymers | 1 | 2002 | 7 | 0.180 |
Why?
|
| Prevalence | 4 | 2025 | 259 | 0.180 |
Why?
|
| Blood Specimen Collection | 2 | 2018 | 5 | 0.180 |
Why?
|
| Placebo Effect | 1 | 2022 | 5 | 0.180 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2021 | 1 | 0.180 |
Why?
|
| Healthcare Disparities | 2 | 2022 | 83 | 0.180 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2021 | 2 | 0.180 |
Why?
|
| Endosonography | 1 | 2021 | 3 | 0.180 |
Why?
|
| Lipopolysaccharides | 2 | 2017 | 41 | 0.180 |
Why?
|
| Receptors, CCR6 | 1 | 2021 | 1 | 0.180 |
Why?
|
| Calcium-Binding Proteins | 2 | 2019 | 8 | 0.180 |
Why?
|
| Taurocholic Acid | 2 | 2001 | 2 | 0.180 |
Why?
|
| Osteoporosis | 1 | 2021 | 12 | 0.180 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2021 | 7 | 0.180 |
Why?
|
| Double-Blind Method | 1 | 2022 | 101 | 0.180 |
Why?
|
| Mannosephosphates | 1 | 2021 | 1 | 0.180 |
Why?
|
| Monocytes | 1 | 2021 | 14 | 0.180 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2024 | 11 | 0.180 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2021 | 5 | 0.180 |
Why?
|
| Cachexia | 1 | 2021 | 25 | 0.180 |
Why?
|
| Reproducibility of Results | 4 | 2024 | 112 | 0.170 |
Why?
|
| Cholesterol | 1 | 2021 | 37 | 0.170 |
Why?
|
| Regulatory Factor X Transcription Factors | 2 | 2011 | 2 | 0.170 |
Why?
|
| Genomics | 1 | 2021 | 13 | 0.170 |
Why?
|
| Receptors, Cell Surface | 5 | 2015 | 29 | 0.170 |
Why?
|
| Life Expectancy | 1 | 2021 | 10 | 0.170 |
Why?
|
| Pain Measurement | 3 | 2026 | 51 | 0.170 |
Why?
|
| Nucleic Acids | 1 | 2021 | 1 | 0.170 |
Why?
|
| Peroxidase | 2 | 2019 | 3 | 0.170 |
Why?
|
| Immunoblotting | 4 | 2009 | 16 | 0.170 |
Why?
|
| Acetyl Coenzyme A | 1 | 2020 | 2 | 0.170 |
Why?
|
| Immunoenzyme Techniques | 2 | 2016 | 14 | 0.170 |
Why?
|
| Membrane Transport Proteins | 1 | 2020 | 3 | 0.170 |
Why?
|
| Liquid Biopsy | 1 | 2020 | 1 | 0.170 |
Why?
|
| Organ Specificity | 1 | 2020 | 10 | 0.170 |
Why?
|
| Cell Adhesion | 1 | 2000 | 19 | 0.170 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2000 | 9 | 0.170 |
Why?
|
| Hypoglycemic Agents | 2 | 2019 | 165 | 0.170 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 8 | 0.170 |
Why?
|
| Adaptive Immunity | 2 | 2021 | 3 | 0.160 |
Why?
|
| Phosphoproteins | 2 | 2015 | 9 | 0.160 |
Why?
|
| Exocytosis | 3 | 2007 | 4 | 0.160 |
Why?
|
| Mice, Transgenic | 5 | 2022 | 59 | 0.160 |
Why?
|
| Transforming Growth Factor beta1 | 3 | 2024 | 20 | 0.160 |
Why?
|
| Cigar Smoking | 1 | 2020 | 1 | 0.160 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 35 | 0.160 |
Why?
|
| Menthol | 1 | 2020 | 2 | 0.160 |
Why?
|
| Pilot Projects | 3 | 2026 | 89 | 0.160 |
Why?
|
| Neuroendocrine Cells | 1 | 2020 | 1 | 0.160 |
Why?
|
| Natural Language Processing | 1 | 2020 | 9 | 0.160 |
Why?
|
| Carboxylesterase | 1 | 2020 | 1 | 0.160 |
Why?
|
| New Zealand | 4 | 2021 | 5 | 0.160 |
Why?
|
| Immunity, Mucosal | 1 | 2020 | 2 | 0.160 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 7 | 2004 | 9 | 0.160 |
Why?
|
| Luminescent Proteins | 1 | 2019 | 2 | 0.160 |
Why?
|
| Green Fluorescent Proteins | 1 | 2019 | 7 | 0.160 |
Why?
|
| Antiviral Agents | 1 | 2020 | 53 | 0.160 |
Why?
|
| Neural Stem Cells | 1 | 2020 | 8 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2019 | 7 | 0.160 |
Why?
|
| Endoscopy | 1 | 2019 | 7 | 0.160 |
Why?
|
| DNA | 4 | 2019 | 39 | 0.160 |
Why?
|
| Acetophenones | 2 | 2009 | 2 | 0.160 |
Why?
|
| Arachidonic Acids | 3 | 2024 | 8 | 0.160 |
Why?
|
| Conservative Treatment | 1 | 2019 | 10 | 0.150 |
Why?
|
| Membrane Fusion | 1 | 2019 | 1 | 0.150 |
Why?
|
| Quality Indicators, Health Care | 1 | 2019 | 7 | 0.150 |
Why?
|
| Genetic Engineering | 1 | 2019 | 2 | 0.150 |
Why?
|
| Metabolic Syndrome | 1 | 2020 | 35 | 0.150 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2019 | 2 | 0.150 |
Why?
|
| Vitamin D | 1 | 2020 | 45 | 0.150 |
Why?
|
| Urocortins | 1 | 2019 | 1 | 0.150 |
Why?
|
| Vasoactive Intestinal Peptide | 7 | 1990 | 8 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 12 | 0.150 |
Why?
|
| Protein Binding | 4 | 2020 | 29 | 0.150 |
Why?
|
| Energy Intake | 2 | 2017 | 30 | 0.150 |
Why?
|
| Dietary Supplements | 1 | 2019 | 44 | 0.150 |
Why?
|
| Colonic Neoplasms | 1 | 2019 | 4 | 0.150 |
Why?
|
| Caspase 9 | 4 | 2009 | 7 | 0.150 |
Why?
|
| Inflammasomes | 1 | 2019 | 10 | 0.150 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2019 | 21 | 0.150 |
Why?
|
| Invertebrate Hormones | 1 | 1999 | 1 | 0.150 |
Why?
|
| Acetylation | 2 | 2016 | 10 | 0.150 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2016 | 15 | 0.150 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 5 | 0.150 |
Why?
|
| Treatment Outcome | 4 | 2026 | 500 | 0.150 |
Why?
|
| Th17 Cells | 1 | 2019 | 4 | 0.150 |
Why?
|
| Alarmins | 1 | 2019 | 1 | 0.150 |
Why?
|
| Multivariate Analysis | 4 | 2024 | 104 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2025 | 14 | 0.150 |
Why?
|
| Triglycerides | 2 | 2017 | 58 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2015 | 11 | 0.150 |
Why?
|
| Staining and Labeling | 1 | 2018 | 10 | 0.150 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 2 | 2010 | 2 | 0.150 |
Why?
|
| Biological Specimen Banks | 1 | 2018 | 2 | 0.150 |
Why?
|
| Preservation, Biological | 1 | 2018 | 2 | 0.150 |
Why?
|
| Cell Membrane Permeability | 4 | 2000 | 7 | 0.150 |
Why?
|
| Antibodies | 4 | 2016 | 16 | 0.150 |
Why?
|
| Health Status | 1 | 2019 | 83 | 0.150 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 19 | 0.140 |
Why?
|
| ROC Curve | 3 | 2024 | 28 | 0.140 |
Why?
|
| Research Support as Topic | 1 | 2018 | 20 | 0.140 |
Why?
|
| Liver Diseases | 1 | 2018 | 19 | 0.140 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 2 | 2022 | 4 | 0.140 |
Why?
|
| Gene Expression | 5 | 2020 | 77 | 0.140 |
Why?
|
| Phenotype | 3 | 2024 | 91 | 0.140 |
Why?
|
| Protein Transport | 3 | 2019 | 23 | 0.140 |
Why?
|
| Japan | 2 | 2015 | 6 | 0.140 |
Why?
|
| Nuclear Proteins | 3 | 2007 | 17 | 0.140 |
Why?
|
| Antioxidants | 6 | 2021 | 37 | 0.140 |
Why?
|
| Matrix Metalloproteinase 2 | 3 | 2008 | 8 | 0.140 |
Why?
|
| Acyl Coenzyme A | 1 | 1997 | 1 | 0.140 |
Why?
|
| Logistic Models | 3 | 2024 | 165 | 0.140 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1997 | 4 | 0.140 |
Why?
|
| Chymotrypsin | 1 | 2017 | 5 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 2 | 0.130 |
Why?
|
| Macrophage Activation | 1 | 2017 | 3 | 0.130 |
Why?
|
| Adoptive Transfer | 1 | 2017 | 3 | 0.130 |
Why?
|
| Cadaver | 1 | 2017 | 12 | 0.130 |
Why?
|
| Immune Tolerance | 1 | 2017 | 8 | 0.130 |
Why?
|
| Insulin Resistance | 3 | 2024 | 74 | 0.130 |
Why?
|
| Myosins | 1 | 1997 | 1 | 0.130 |
Why?
|
| Cytoplasmic Granules | 1 | 1997 | 2 | 0.130 |
Why?
|
| Microscopy, Electron | 6 | 2007 | 21 | 0.130 |
Why?
|
| Sex Factors | 3 | 2024 | 155 | 0.130 |
Why?
|
| Temperature | 3 | 2020 | 8 | 0.130 |
Why?
|
| Secretin | 4 | 2024 | 13 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2002 | 90 | 0.130 |
Why?
|
| Ileum | 2 | 2014 | 7 | 0.130 |
Why?
|
| Cation Exchange Resins | 1 | 2017 | 1 | 0.130 |
Why?
|
| Endotoxemia | 1 | 2017 | 2 | 0.130 |
Why?
|
| Polystyrenes | 1 | 2017 | 2 | 0.130 |
Why?
|
| Cathepsin H | 1 | 2017 | 1 | 0.130 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2017 | 2 | 0.130 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 13 | 0.130 |
Why?
|
| Precipitin Tests | 3 | 2004 | 4 | 0.130 |
Why?
|
| Janus Kinase 2 | 2 | 2007 | 5 | 0.130 |
Why?
|
| Polyribosomes | 2 | 1997 | 2 | 0.130 |
Why?
|
| Mitochondrial Proteins | 2 | 2015 | 15 | 0.130 |
Why?
|
| Aminoquinolines | 5 | 1993 | 7 | 0.130 |
Why?
|
| Amino Acid Substitution | 2 | 2017 | 6 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 9 | 0.130 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2016 | 3 | 0.130 |
Why?
|
| Interleukins | 1 | 2016 | 8 | 0.130 |
Why?
|
| Cell Nucleus | 3 | 2017 | 38 | 0.130 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 140 | 0.130 |
Why?
|
| Atropine | 11 | 1989 | 17 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 38 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 36 | 0.120 |
Why?
|
| Proportional Hazards Models | 4 | 2021 | 169 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2016 | 15 | 0.120 |
Why?
|
| Enteroendocrine Cells | 1 | 2016 | 2 | 0.120 |
Why?
|
| Inositol Phosphates | 5 | 2015 | 7 | 0.120 |
Why?
|
| Laminin | 3 | 2005 | 5 | 0.120 |
Why?
|
| Receptor, EphA2 | 1 | 2016 | 1 | 0.120 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2016 | 2 | 0.120 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 18 | 0.120 |
Why?
|
| Nitrosamines | 2 | 2013 | 6 | 0.120 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2016 | 2 | 0.120 |
Why?
|
| Glucagon | 3 | 2024 | 8 | 0.120 |
Why?
|
| Homeodomain Proteins | 1 | 2016 | 11 | 0.120 |
Why?
|
| Chlorides | 5 | 1995 | 12 | 0.120 |
Why?
|
| Nitric Oxide Synthase | 4 | 2005 | 39 | 0.120 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2 | 2006 | 2 | 0.120 |
Why?
|
| Chromones | 2 | 2006 | 6 | 0.120 |
Why?
|
| Morpholines | 2 | 2006 | 6 | 0.120 |
Why?
|
| Indoles | 2 | 2009 | 11 | 0.120 |
Why?
|
| Adolescent | 4 | 2026 | 869 | 0.120 |
Why?
|
| Lovastatin | 1 | 2015 | 2 | 0.120 |
Why?
|
| Glycerides | 2 | 2024 | 3 | 0.120 |
Why?
|
| Down-Regulation | 3 | 2021 | 57 | 0.120 |
Why?
|
| Subcellular Fractions | 3 | 2017 | 8 | 0.120 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2015 | 3 | 0.110 |
Why?
|
| Fibrinolysin | 2 | 2006 | 2 | 0.110 |
Why?
|
| Ionomycin | 6 | 2006 | 6 | 0.110 |
Why?
|
| Neoplasm Metastasis | 3 | 2025 | 22 | 0.110 |
Why?
|
| Diglycerides | 4 | 1993 | 5 | 0.110 |
Why?
|
| Cyclosporine | 2 | 2007 | 7 | 0.110 |
Why?
|
| Bcl-2-Like Protein 11 | 2 | 2012 | 2 | 0.110 |
Why?
|
| Digestive System | 1 | 1995 | 6 | 0.110 |
Why?
|
| Sphingosine | 1 | 1994 | 1 | 0.110 |
Why?
|
| Cyclic AMP | 8 | 1995 | 30 | 0.110 |
Why?
|
| International Cooperation | 1 | 2014 | 8 | 0.110 |
Why?
|
| Congresses as Topic | 1 | 2014 | 20 | 0.110 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2014 | 1 | 0.110 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2014 | 1 | 0.110 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2014 | 3 | 0.110 |
Why?
|
| Global Health | 2 | 2023 | 54 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 24 | 0.110 |
Why?
|
| Cytokine Receptor gp130 | 2 | 2024 | 3 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 3 | 2016 | 55 | 0.110 |
Why?
|
| I-kappa B Proteins | 3 | 2008 | 4 | 0.100 |
Why?
|
| Phytochemicals | 1 | 2013 | 3 | 0.100 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2003 | 8 | 0.100 |
Why?
|
| Plant Extracts | 1 | 2013 | 10 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 16 | 0.100 |
Why?
|
| Nitric Oxide | 1 | 1994 | 47 | 0.100 |
Why?
|
| Flow Cytometry | 3 | 2021 | 48 | 0.100 |
Why?
|
| Fura-2 | 5 | 1994 | 6 | 0.100 |
Why?
|
| Benzamides | 2 | 2010 | 11 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2025 | 23 | 0.100 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2004 | 7 | 0.100 |
Why?
|
| Comorbidity | 3 | 2019 | 147 | 0.100 |
Why?
|
| Isoenzymes | 2 | 2004 | 15 | 0.100 |
Why?
|
| Epithelial Cells | 2 | 2024 | 49 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 3 | 2019 | 8 | 0.100 |
Why?
|
| Cathepsins | 3 | 2024 | 12 | 0.100 |
Why?
|
| Age Factors | 2 | 2026 | 193 | 0.100 |
Why?
|
| Acetaldehyde | 2 | 2003 | 3 | 0.100 |
Why?
|
| Substance P | 3 | 2007 | 9 | 0.100 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2010 | 34 | 0.100 |
Why?
|
| Apigenin | 1 | 2012 | 1 | 0.100 |
Why?
|
| Calcium Channels | 2 | 2008 | 8 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 2 | 2019 | 43 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 82 | 0.090 |
Why?
|
| Protein Conformation | 1 | 2012 | 5 | 0.090 |
Why?
|
| Colon | 3 | 1995 | 20 | 0.090 |
Why?
|
| Consensus | 2 | 2024 | 39 | 0.090 |
Why?
|
| Feasibility Studies | 2 | 2023 | 44 | 0.090 |
Why?
|
| Educational Status | 2 | 2024 | 61 | 0.090 |
Why?
|
| Environment | 1 | 2012 | 3 | 0.090 |
Why?
|
| NADPH Oxidase 4 | 5 | 2013 | 5 | 0.090 |
Why?
|
| Prostate | 2 | 2024 | 15 | 0.090 |
Why?
|
| Sodium | 2 | 1991 | 43 | 0.090 |
Why?
|
| Cisplatin | 2 | 2023 | 9 | 0.090 |
Why?
|
| Administration, Oral | 3 | 2017 | 54 | 0.090 |
Why?
|
| Protein Isoforms | 4 | 2008 | 12 | 0.090 |
Why?
|
| Cathepsin L | 2 | 2024 | 3 | 0.090 |
Why?
|
| NF-KappaB Inhibitor alpha | 2 | 2019 | 3 | 0.090 |
Why?
|
| Enzymes | 1 | 1991 | 5 | 0.090 |
Why?
|
| Vacuoles | 2 | 2009 | 2 | 0.090 |
Why?
|
| Abdomen | 2 | 2022 | 3 | 0.090 |
Why?
|
| Blood Glucose | 2 | 2024 | 188 | 0.090 |
Why?
|
| Biological Transport | 4 | 2003 | 22 | 0.090 |
Why?
|
| DNA Fragmentation | 3 | 2013 | 7 | 0.080 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2010 | 1 | 0.080 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2010 | 1 | 0.080 |
Why?
|
| Isoquinolines | 4 | 1995 | 9 | 0.080 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 17 | 0.080 |
Why?
|
| Adaptation, Physiological | 1 | 2010 | 13 | 0.080 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2007 | 3 | 0.080 |
Why?
|
| Molecular Chaperones | 1 | 2010 | 7 | 0.080 |
Why?
|
| Heat-Shock Proteins | 1 | 2010 | 9 | 0.080 |
Why?
|
| Sugar Phosphates | 2 | 1988 | 2 | 0.080 |
Why?
|
| SEER Program | 2 | 2024 | 9 | 0.080 |
Why?
|
| Rabbits | 5 | 1997 | 48 | 0.080 |
Why?
|
| Piperazines | 4 | 1995 | 21 | 0.080 |
Why?
|
| Egtazic Acid | 4 | 1997 | 4 | 0.080 |
Why?
|
| Carrier Proteins | 2 | 2003 | 28 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2010 | 17 | 0.080 |
Why?
|
| Vagotomy | 1 | 2010 | 1 | 0.080 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2010 | 13 | 0.080 |
Why?
|
| Munc18 Proteins | 2 | 2007 | 2 | 0.080 |
Why?
|
| Nitriles | 1 | 2010 | 13 | 0.080 |
Why?
|
| Observational Studies as Topic | 2 | 2021 | 9 | 0.080 |
Why?
|
| Host-Pathogen Interactions | 2 | 2020 | 3 | 0.080 |
Why?
|
| Fibroblast Growth Factors | 2 | 2024 | 10 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 50 | 0.080 |
Why?
|
| Cell Fusion | 2 | 2020 | 3 | 0.080 |
Why?
|
| Interdisciplinary Communication | 2 | 2021 | 7 | 0.080 |
Why?
|
| Type C Phospholipases | 2 | 2004 | 2 | 0.080 |
Why?
|
| Capsid Proteins | 2 | 2026 | 2 | 0.080 |
Why?
|
| Maleimides | 1 | 2009 | 5 | 0.080 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2009 | 3 | 0.080 |
Why?
|
| Cell Separation | 2 | 2021 | 6 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2009 | 1 | 0.080 |
Why?
|
| Electronic Health Records | 2 | 2020 | 34 | 0.080 |
Why?
|
| Cysteine Endopeptidases | 1 | 2009 | 13 | 0.080 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 26 | 0.080 |
Why?
|
| Antigens, CD | 2 | 2020 | 21 | 0.080 |
Why?
|
| Rats, Inbred Strains | 6 | 1991 | 49 | 0.080 |
Why?
|
| Base Sequence | 2 | 2009 | 65 | 0.080 |
Why?
|
| Palmitoyl Coenzyme A | 2 | 2000 | 2 | 0.080 |
Why?
|
| Transfection | 3 | 2007 | 56 | 0.080 |
Why?
|
| Ionophores | 1 | 1989 | 1 | 0.080 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2026 | 6 | 0.080 |
Why?
|
| Deuterium Oxide | 1 | 2009 | 1 | 0.070 |
Why?
|
| Stearic Acids | 1 | 2009 | 2 | 0.070 |
Why?
|
| Oleic Acid | 1 | 2009 | 4 | 0.070 |
Why?
|
| Palmitic Acid | 1 | 2009 | 3 | 0.070 |
Why?
|
| Gallstones | 2 | 2019 | 6 | 0.070 |
Why?
|
| Benzofurans | 4 | 1990 | 4 | 0.070 |
Why?
|
| Caspase Inhibitors | 2 | 2006 | 5 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 2 | 1986 | 25 | 0.070 |
Why?
|
| Nerve Growth Factors | 1 | 2008 | 4 | 0.070 |
Why?
|
| Serpins | 1 | 2008 | 5 | 0.070 |
Why?
|
| Hydroquinones | 2 | 2000 | 2 | 0.070 |
Why?
|
| Eye Proteins | 1 | 2008 | 10 | 0.070 |
Why?
|
| Ornithine | 1 | 2008 | 3 | 0.070 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 4 | 1995 | 7 | 0.070 |
Why?
|
| Glucagon-Secreting Cells | 1 | 2008 | 2 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2023 | 18 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 4 | 2003 | 72 | 0.070 |
Why?
|
| Gastrointestinal Hormones | 2 | 2024 | 5 | 0.070 |
Why?
|
| Soluble N-Ethylmaleimide-Sensitive Factor Attachment Proteins | 1 | 2007 | 1 | 0.070 |
Why?
|
| Cholagogues and Choleretics | 1 | 2007 | 1 | 0.070 |
Why?
|
| Protein Kinase C-alpha | 1 | 2007 | 2 | 0.070 |
Why?
|
| Choline | 2 | 2022 | 7 | 0.060 |
Why?
|
| Androstadienes | 1 | 2006 | 1 | 0.060 |
Why?
|
| Taurochenodeoxycholic Acid | 1 | 2006 | 1 | 0.060 |
Why?
|
| Taurolithocholic Acid | 1 | 2006 | 1 | 0.060 |
Why?
|
| Cell Compartmentation | 2 | 1997 | 3 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2006 | 2 | 0.060 |
Why?
|
| Ligands | 2 | 2016 | 17 | 0.060 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2006 | 1 | 0.060 |
Why?
|
| STAT Transcription Factors | 1 | 2006 | 1 | 0.060 |
Why?
|
| Sp1 Transcription Factor | 1 | 2006 | 3 | 0.060 |
Why?
|
| Saliva | 1 | 2026 | 7 | 0.060 |
Why?
|
| Feces | 1 | 2026 | 7 | 0.060 |
Why?
|
| Diet, Mediterranean | 1 | 2026 | 4 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2006 | 20 | 0.060 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2026 | 3 | 0.060 |
Why?
|
| Self-Management | 1 | 2026 | 3 | 0.060 |
Why?
|
| Membrane Potential, Mitochondrial | 3 | 2012 | 8 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2026 | 82 | 0.060 |
Why?
|
| Interleukin-4 | 2 | 2016 | 9 | 0.060 |
Why?
|
| Collagen Type I | 3 | 2016 | 18 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2026 | 58 | 0.060 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 2005 | 1 | 0.060 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2005 | 5 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 20 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 70 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 5 | 0.060 |
Why?
|
| Alcohol-Related Disorders | 1 | 2005 | 5 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2005 | 63 | 0.060 |
Why?
|
| Phosphatidylinositols | 1 | 1985 | 1 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 42 | 0.060 |
Why?
|
| Cellular Senescence | 1 | 2025 | 8 | 0.060 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2025 | 6 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 79 | 0.060 |
Why?
|
| CA-19-9 Antigen | 1 | 2024 | 2 | 0.060 |
Why?
|
| Vesicular Transport Proteins | 1 | 2024 | 3 | 0.060 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1997 | 7 | 0.060 |
Why?
|
| Ethanolamines | 1 | 2024 | 2 | 0.050 |
Why?
|
| Palmitic Acids | 1 | 2024 | 2 | 0.050 |
Why?
|
| Polyunsaturated Alkamides | 1 | 2024 | 3 | 0.050 |
Why?
|
| Oleic Acids | 1 | 2024 | 3 | 0.050 |
Why?
|
| Amides | 1 | 2024 | 4 | 0.050 |
Why?
|
| Duodenal Neoplasms | 1 | 2024 | 1 | 0.050 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2024 | 1 | 0.050 |
Why?
|
| Thinness | 1 | 2024 | 4 | 0.050 |
Why?
|
| Energy Metabolism | 2 | 2018 | 21 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2010 | 14 | 0.050 |
Why?
|
| Pancreatic Hormones | 1 | 2024 | 1 | 0.050 |
Why?
|
| Growth Hormone-Releasing Hormone | 1 | 1984 | 4 | 0.050 |
Why?
|
| Peptide YY | 1 | 2024 | 4 | 0.050 |
Why?
|
| C-Peptide | 1 | 2024 | 8 | 0.050 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2024 | 2 | 0.050 |
Why?
|
| Postprandial Period | 1 | 2024 | 4 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2024 | 6 | 0.050 |
Why?
|
| Diuretics | 1 | 2024 | 13 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2024 | 15 | 0.050 |
Why?
|
| Substrate Specificity | 1 | 2004 | 10 | 0.050 |
Why?
|
| src-Family Kinases | 1 | 2004 | 7 | 0.050 |
Why?
|
| Retreatment | 1 | 2024 | 5 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2024 | 81 | 0.050 |
Why?
|
| Linoleic Acid | 1 | 2024 | 3 | 0.050 |
Why?
|
| Nomograms | 1 | 2024 | 1 | 0.050 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2024 | 1 | 0.050 |
Why?
|
| Vitamin A | 1 | 2024 | 3 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2024 | 17 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2024 | 12 | 0.050 |
Why?
|
| Serum Albumin | 1 | 2024 | 50 | 0.050 |
Why?
|
| Carbocyanines | 1 | 2024 | 1 | 0.050 |
Why?
|
| Income | 1 | 2024 | 30 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2023 | 8 | 0.050 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2003 | 5 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2023 | 10 | 0.050 |
Why?
|
| Microsomes | 2 | 1994 | 4 | 0.050 |
Why?
|
| Polyhydroxyethyl Methacrylate | 1 | 2003 | 1 | 0.050 |
Why?
|
| Zollinger-Ellison Syndrome | 5 | 1983 | 5 | 0.050 |
Why?
|
| Alkaloids | 2 | 1995 | 2 | 0.050 |
Why?
|
| Nociception | 1 | 2023 | 3 | 0.050 |
Why?
|
| Staurosporine | 2 | 1995 | 4 | 0.050 |
Why?
|
| Acetates | 2 | 2002 | 6 | 0.050 |
Why?
|
| Cell Differentiation | 2 | 2020 | 101 | 0.050 |
Why?
|
| Microscopy, Confocal | 2 | 2007 | 11 | 0.050 |
Why?
|
| DNA Damage | 2 | 2021 | 20 | 0.050 |
Why?
|
| Genistein | 1 | 2003 | 1 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2016 | 38 | 0.050 |
Why?
|
| Collagenases | 1 | 2022 | 3 | 0.050 |
Why?
|
| Ethionine | 1 | 2002 | 1 | 0.050 |
Why?
|
| Gallbladder | 1 | 2002 | 1 | 0.050 |
Why?
|
| Choline Deficiency | 1 | 2002 | 6 | 0.050 |
Why?
|
| Tretinoin | 1 | 2022 | 30 | 0.050 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2022 | 2 | 0.050 |
Why?
|
| Polyethylene Glycols | 1 | 2022 | 4 | 0.050 |
Why?
|
| Dextran Sulfate | 1 | 2022 | 3 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 8 | 0.050 |
Why?
|
| Water | 1 | 2022 | 13 | 0.050 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2002 | 4 | 0.050 |
Why?
|
| Annexin A5 | 1 | 2002 | 1 | 0.050 |
Why?
|
| Intermediate Filament Proteins | 1 | 2002 | 1 | 0.050 |
Why?
|
| Transcriptome | 1 | 2022 | 31 | 0.050 |
Why?
|
| Estrogens | 1 | 2022 | 27 | 0.050 |
Why?
|
| Food | 1 | 2002 | 8 | 0.050 |
Why?
|
| Kidney | 1 | 2024 | 184 | 0.050 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2002 | 2 | 0.050 |
Why?
|
| Acyltransferases | 1 | 2002 | 2 | 0.050 |
Why?
|
| Rosuvastatin Calcium | 1 | 2021 | 2 | 0.050 |
Why?
|
| Ethers | 4 | 1989 | 4 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 25 | 0.050 |
Why?
|
| Chemokine CCL20 | 1 | 2021 | 1 | 0.040 |
Why?
|
| Carbohydrates | 1 | 2021 | 5 | 0.040 |
Why?
|
| Brain | 1 | 2022 | 94 | 0.040 |
Why?
|
| Mental Health | 1 | 2022 | 70 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2021 | 5 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 9 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2021 | 11 | 0.040 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 1 | 2021 | 1 | 0.040 |
Why?
|
| Bone Density | 1 | 2021 | 25 | 0.040 |
Why?
|
| Sample Size | 1 | 2021 | 3 | 0.040 |
Why?
|
| Arginine | 2 | 2008 | 20 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2017 | 45 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2001 | 27 | 0.040 |
Why?
|
| Health Risk Behaviors | 1 | 2021 | 5 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2021 | 17 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2001 | 26 | 0.040 |
Why?
|
| Phospholipases A2 | 2 | 1991 | 3 | 0.040 |
Why?
|
| Phospholipases A | 2 | 1991 | 6 | 0.040 |
Why?
|
| Phosphatidylcholines | 2 | 1991 | 6 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 2021 | 9 | 0.040 |
Why?
|
| Endoscopy, Digestive System | 1 | 2021 | 1 | 0.040 |
Why?
|
| Ribonucleases | 1 | 2021 | 2 | 0.040 |
Why?
|
| RNA Stability | 1 | 2021 | 3 | 0.040 |
Why?
|
| Protein Stability | 1 | 2021 | 3 | 0.040 |
Why?
|
| Freezing | 1 | 2021 | 4 | 0.040 |
Why?
|
| Cold Temperature | 1 | 2021 | 5 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 2021 | 11 | 0.040 |
Why?
|
| Workflow | 1 | 2021 | 7 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 10 | 0.040 |
Why?
|
| Depression | 1 | 2022 | 128 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2022 | 83 | 0.040 |
Why?
|
| Veterans | 1 | 2021 | 70 | 0.040 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2020 | 1 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 95 | 0.040 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2000 | 2 | 0.040 |
Why?
|
| Cell Polarity | 1 | 2000 | 3 | 0.040 |
Why?
|
| Leupeptins | 1 | 2000 | 4 | 0.040 |
Why?
|
| Molecular Weight | 1 | 2000 | 7 | 0.040 |
Why?
|
| SRS-A | 2 | 1990 | 2 | 0.040 |
Why?
|
| Nitroprusside | 2 | 1990 | 3 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2000 | 40 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2020 | 3 | 0.040 |
Why?
|
| T-Lymphocytes | 2 | 2018 | 20 | 0.040 |
Why?
|
| Cause of Death | 1 | 2021 | 82 | 0.040 |
Why?
|
| Adenoma, Islet Cell | 1 | 1980 | 2 | 0.040 |
Why?
|
| Lithium | 1 | 1980 | 4 | 0.040 |
Why?
|
| Calcium Radioisotopes | 3 | 1989 | 4 | 0.040 |
Why?
|
| Diarrhea | 1 | 1980 | 10 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 17 | 0.040 |
Why?
|
| Thiadiazoles | 1 | 2020 | 1 | 0.040 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2020 | 1 | 0.040 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 2020 | 1 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2020 | 2 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2020 | 7 | 0.040 |
Why?
|
| Oncogenes | 1 | 2020 | 4 | 0.040 |
Why?
|
| Pressure | 1 | 2020 | 7 | 0.040 |
Why?
|
| TRPM Cation Channels | 1 | 2020 | 1 | 0.040 |
Why?
|
| Virus Replication | 1 | 2020 | 7 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2020 | 15 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2020 | 13 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 2020 | 19 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2020 | 11 | 0.040 |
Why?
|
| Pyrazines | 1 | 2020 | 17 | 0.040 |
Why?
|
| Cell Fractionation | 1 | 2000 | 5 | 0.040 |
Why?
|
| Endocytosis | 1 | 2020 | 3 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2020 | 16 | 0.040 |
Why?
|
| Trypsin Inhibitors | 1 | 2020 | 1 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 10 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 40 | 0.040 |
Why?
|
| Contrast Media | 1 | 2020 | 18 | 0.040 |
Why?
|
| Receptors, Calcitriol | 1 | 2020 | 16 | 0.040 |
Why?
|
| Neurosecretory Systems | 1 | 2020 | 8 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2020 | 14 | 0.040 |
Why?
|
| Imidazoles | 2 | 2000 | 13 | 0.040 |
Why?
|
| Social Media | 1 | 2020 | 13 | 0.040 |
Why?
|
| Gastroenterologists | 1 | 2019 | 1 | 0.040 |
Why?
|
| Cholecystectomy | 1 | 2019 | 4 | 0.040 |
Why?
|
| Nutritional Support | 1 | 2019 | 4 | 0.040 |
Why?
|
| Analgesics | 1 | 2019 | 12 | 0.040 |
Why?
|
| Surgeons | 1 | 2019 | 7 | 0.040 |
Why?
|
| Genotype | 1 | 2019 | 28 | 0.040 |
Why?
|
| Pregnancy | 1 | 2021 | 599 | 0.040 |
Why?
|
| Hospitalists | 1 | 2019 | 6 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2019 | 17 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2019 | 23 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2019 | 9 | 0.040 |
Why?
|
| Endosomes | 1 | 2019 | 2 | 0.040 |
Why?
|
| Oligopeptides | 1 | 1999 | 4 | 0.040 |
Why?
|
| Second Messenger Systems | 3 | 1994 | 6 | 0.040 |
Why?
|
| Gastrointestinal Agents | 2 | 2010 | 6 | 0.040 |
Why?
|
| Chelating Agents | 2 | 1997 | 13 | 0.040 |
Why?
|
| Mortality | 1 | 2019 | 43 | 0.040 |
Why?
|
| Isomerism | 1 | 1998 | 1 | 0.040 |
Why?
|
| Population | 1 | 2018 | 2 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2018 | 2 | 0.040 |
Why?
|
| Acetylcysteine | 1 | 1998 | 9 | 0.040 |
Why?
|
| Metformin | 1 | 2019 | 35 | 0.040 |
Why?
|
| Calcium Chloride | 2 | 1997 | 2 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2018 | 26 | 0.040 |
Why?
|
| Dibutyryl Cyclic GMP | 2 | 1990 | 2 | 0.040 |
Why?
|
| Nucleotides, Cyclic | 1 | 2018 | 2 | 0.030 |
Why?
|
| Dictyostelium | 1 | 1998 | 1 | 0.030 |
Why?
|
| Pinocytosis | 1 | 1998 | 2 | 0.030 |
Why?
|
| Phosphatidylinositol Phosphates | 1 | 1998 | 2 | 0.030 |
Why?
|
| Ryanodine | 1 | 1997 | 2 | 0.030 |
Why?
|
| Caffeine | 1 | 1997 | 3 | 0.030 |
Why?
|
| Neutralization Tests | 1 | 1997 | 1 | 0.030 |
Why?
|
| Biological Assay | 1 | 1997 | 4 | 0.030 |
Why?
|
| Hyperinsulinism | 1 | 2017 | 6 | 0.030 |
Why?
|
| Exome | 1 | 2017 | 2 | 0.030 |
Why?
|
| Codon | 1 | 2017 | 2 | 0.030 |
Why?
|
| Submandibular Gland | 1 | 1997 | 1 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1997 | 35 | 0.030 |
Why?
|
| Computational Biology | 1 | 2017 | 13 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 1997 | 38 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2017 | 40 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 23 | 0.030 |
Why?
|
| Endotoxins | 1 | 2017 | 2 | 0.030 |
Why?
|
| Symbiosis | 1 | 2017 | 2 | 0.030 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2017 | 2 | 0.030 |
Why?
|
| SNARE Proteins | 2 | 2007 | 2 | 0.030 |
Why?
|
| Gastric Mucosa | 2 | 1988 | 6 | 0.030 |
Why?
|
| Dysbiosis | 1 | 2017 | 10 | 0.030 |
Why?
|
| Enzyme Stability | 1 | 2017 | 1 | 0.030 |
Why?
|
| Biocatalysis | 1 | 2017 | 3 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 13 | 0.030 |
Why?
|
| Myofibroblasts | 1 | 2017 | 7 | 0.030 |
Why?
|
| Cell Transdifferentiation | 1 | 2017 | 8 | 0.030 |
Why?
|
| Polychlorinated Dibenzodioxins | 1 | 2016 | 1 | 0.030 |
Why?
|
| Receptors, Interleukin | 1 | 2016 | 1 | 0.030 |
Why?
|
| Benzo(a)pyrene | 1 | 2016 | 2 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2016 | 2 | 0.030 |
Why?
|
| Diterpenes | 1 | 1996 | 2 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2016 | 23 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 25 | 0.030 |
Why?
|
| Platelet Activating Factor | 1 | 1996 | 19 | 0.030 |
Why?
|
| Hawaii | 1 | 2016 | 6 | 0.030 |
Why?
|
| Tobacco Products | 1 | 2016 | 14 | 0.030 |
Why?
|
| Gastric Acid | 4 | 1983 | 4 | 0.030 |
Why?
|
| Transcription Factor CHOP | 1 | 2016 | 1 | 0.030 |
Why?
|
| eIF-2 Kinase | 1 | 2016 | 2 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 14 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 28 | 0.030 |
Why?
|
| Calcitonin Gene-Related Peptide | 2 | 1986 | 4 | 0.030 |
Why?
|
| American Medical Association | 1 | 2015 | 2 | 0.030 |
Why?
|
| Hypercalcemia | 1 | 1995 | 11 | 0.030 |
Why?
|
| Potassium | 2 | 1986 | 26 | 0.030 |
Why?
|
| Histones | 1 | 2015 | 13 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 13 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 24 | 0.030 |
Why?
|
| Trifluoperazine | 1 | 1995 | 1 | 0.030 |
Why?
|
| Calmodulin | 1 | 1995 | 2 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 45 | 0.030 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 1995 | 4 | 0.030 |
Why?
|
| Interleukin-13 | 1 | 2015 | 1 | 0.030 |
Why?
|
| Interleukin-4 Receptor alpha Subunit | 1 | 2015 | 1 | 0.030 |
Why?
|
| Leukocytes | 1 | 2015 | 9 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2015 | 24 | 0.030 |
Why?
|
| Sulfonamides | 1 | 1995 | 17 | 0.030 |
Why?
|
| Receptors, Vasoactive Intestinal Peptide | 2 | 1986 | 2 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 111 | 0.030 |
Why?
|
| Organic Anion Transporters, Sodium-Dependent | 1 | 2014 | 1 | 0.030 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2014 | 2 | 0.030 |
Why?
|
| Fatty Acid Synthases | 1 | 2014 | 6 | 0.030 |
Why?
|
| Lipogenesis | 1 | 2014 | 6 | 0.030 |
Why?
|
| Calcitriol | 1 | 2014 | 18 | 0.030 |
Why?
|
| Symporters | 1 | 2014 | 21 | 0.030 |
Why?
|
| Medicare | 1 | 2015 | 57 | 0.030 |
Why?
|
| Acetylcholine | 1 | 1994 | 4 | 0.030 |
Why?
|
| Biological Transport, Active | 3 | 1988 | 4 | 0.030 |
Why?
|
| omega-N-Methylarginine | 1 | 1994 | 1 | 0.030 |
Why?
|
| Nitroarginine | 1 | 1994 | 1 | 0.030 |
Why?
|
| Indomethacin | 1 | 1994 | 4 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2014 | 15 | 0.030 |
Why?
|
| Lanthanum | 3 | 1989 | 7 | 0.030 |
Why?
|
| Adenylate Kinase | 1 | 2013 | 4 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2012 | 1 | 0.020 |
Why?
|
| Propranolol | 1 | 2012 | 5 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 11 | 0.020 |
Why?
|
| Periodicity | 1 | 1992 | 8 | 0.020 |
Why?
|
| Phagocytosis | 2 | 2004 | 18 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1991 | 5 | 0.020 |
Why?
|
| DNA Probes | 1 | 1991 | 5 | 0.020 |
Why?
|
| Cyclohexanones | 1 | 1991 | 1 | 0.020 |
Why?
|
| Lysophosphatidylcholines | 1 | 1991 | 1 | 0.020 |
Why?
|
| Lipoprotein Lipase | 1 | 1991 | 6 | 0.020 |
Why?
|
| Heterozygote | 1 | 2010 | 9 | 0.020 |
Why?
|
| Cathepsin B | 1 | 2010 | 3 | 0.020 |
Why?
|
| Carbazoles | 1 | 2010 | 4 | 0.020 |
Why?
|
| Quaternary Ammonium Compounds | 2 | 1988 | 3 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 1990 | 5 | 0.020 |
Why?
|
| Hydroxylamines | 1 | 1990 | 2 | 0.020 |
Why?
|
| Epithelium | 2 | 1989 | 22 | 0.020 |
Why?
|
| Bethanechol Compounds | 1 | 1990 | 1 | 0.020 |
Why?
|
| Secretory Rate | 1 | 1990 | 1 | 0.020 |
Why?
|
| Bethanechol | 1 | 1990 | 4 | 0.020 |
Why?
|
| bcl-Associated Death Protein | 1 | 2009 | 1 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 18 | 0.020 |
Why?
|
| Fasting | 1 | 2009 | 31 | 0.020 |
Why?
|
| Hydrochloric Acid | 1 | 1989 | 1 | 0.020 |
Why?
|
| Duodenum | 1 | 1989 | 4 | 0.020 |
Why?
|
| Electric Conductivity | 2 | 1986 | 5 | 0.020 |
Why?
|
| Nicotine | 1 | 2011 | 144 | 0.020 |
Why?
|
| Bicarbonates | 1 | 1989 | 16 | 0.020 |
Why?
|
| DNA Primers | 1 | 2009 | 23 | 0.020 |
Why?
|
| Lymphoma | 1 | 1988 | 2 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 1988 | 12 | 0.020 |
Why?
|
| Gelatinases | 1 | 2008 | 1 | 0.020 |
Why?
|
| Hormones | 1 | 1988 | 11 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2008 | 33 | 0.020 |
Why?
|
| alpha-Amylases | 1 | 2008 | 1 | 0.020 |
Why?
|
| Pancreatic alpha-Amylases | 1 | 2008 | 1 | 0.020 |
Why?
|
| Reference Values | 1 | 1988 | 56 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2008 | 14 | 0.020 |
Why?
|
| Citrulline | 1 | 2008 | 10 | 0.020 |
Why?
|
| Sodium-Calcium Exchanger | 1 | 1988 | 1 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2007 | 6 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 14 | 0.020 |
Why?
|
| Integrin beta1 | 1 | 2007 | 1 | 0.020 |
Why?
|
| Integrin beta3 | 1 | 2007 | 1 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2007 | 1 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2007 | 1 | 0.020 |
Why?
|
| Qa-SNARE Proteins | 1 | 2007 | 1 | 0.020 |
Why?
|
| Capillary Permeability | 1 | 2007 | 3 | 0.020 |
Why?
|
| Microscopy, Video | 1 | 2007 | 3 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2007 | 20 | 0.020 |
Why?
|
| Microcirculation | 1 | 2007 | 14 | 0.020 |
Why?
|
| Activating Transcription Factor 3 | 1 | 2006 | 1 | 0.020 |
Why?
|
| Pancreatitis-Associated Proteins | 1 | 2006 | 3 | 0.020 |
Why?
|
| Lectins, C-Type | 1 | 2006 | 5 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 7 | 0.020 |
Why?
|
| Cimetidine | 2 | 1983 | 2 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 29 | 0.020 |
Why?
|
| Tetragastrin | 1 | 1986 | 1 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 1986 | 9 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 1986 | 10 | 0.020 |
Why?
|
| Parietal Cells, Gastric | 1 | 1986 | 1 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 44 | 0.020 |
Why?
|
| Alprostadil | 1 | 1986 | 1 | 0.020 |
Why?
|
| Barium | 1 | 1986 | 1 | 0.020 |
Why?
|
| Bumetanide | 1 | 1986 | 3 | 0.020 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2005 | 1 | 0.010 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2005 | 1 | 0.010 |
Why?
|
| Caspase 7 | 1 | 2005 | 3 | 0.010 |
Why?
|
| Species Specificity | 1 | 2005 | 17 | 0.010 |
Why?
|
| Xanthine Oxidase | 1 | 2005 | 1 | 0.010 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2005 | 2 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2005 | 6 | 0.010 |
Why?
|
| Receptors, Calcitonin | 1 | 1985 | 1 | 0.010 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2005 | 2 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1985 | 11 | 0.010 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2005 | 29 | 0.010 |
Why?
|
| Flavoproteins | 1 | 2004 | 1 | 0.010 |
Why?
|
| Nucleosomes | 1 | 2004 | 1 | 0.010 |
Why?
|
| Phosphatidylserines | 1 | 2004 | 1 | 0.010 |
Why?
|
| NADPH Oxidase 2 | 1 | 2004 | 2 | 0.010 |
Why?
|
| Growth Substances | 1 | 2004 | 10 | 0.010 |
Why?
|
| DNA, Mitochondrial | 1 | 2004 | 9 | 0.010 |
Why?
|
| Pituitary Gland | 1 | 1984 | 40 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 2004 | 7 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2004 | 47 | 0.010 |
Why?
|
| Theophylline | 1 | 1983 | 3 | 0.010 |
Why?
|
| Polyamines | 1 | 2003 | 6 | 0.010 |
Why?
|
| Parathyroid Hormone-Related Protein | 2 | 1995 | 22 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 65 | 0.010 |
Why?
|
| Guanidines | 1 | 1983 | 3 | 0.010 |
Why?
|
| Breast | 1 | 1983 | 9 | 0.010 |
Why?
|
| Erectile Dysfunction | 1 | 1983 | 14 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 40 | 0.010 |
Why?
|
| Carcinoma | 1 | 2003 | 13 | 0.010 |
Why?
|
| Receptors, Bombesin | 1 | 1982 | 1 | 0.010 |
Why?
|
| Chloroquine | 1 | 1982 | 3 | 0.010 |
Why?
|
| Densitometry | 1 | 2002 | 3 | 0.010 |
Why?
|
| Immunoassay | 1 | 2002 | 8 | 0.010 |
Why?
|
| Plectin | 1 | 2002 | 1 | 0.010 |
Why?
|
| Bucladesine | 2 | 1995 | 4 | 0.010 |
Why?
|
| Gastroesophageal Reflux | 1 | 1981 | 3 | 0.010 |
Why?
|
| Chemokine CXCL2 | 1 | 2000 | 2 | 0.010 |
Why?
|
| Chemokines, CXC | 1 | 2000 | 4 | 0.010 |
Why?
|
| Chemokine CXCL1 | 1 | 2000 | 4 | 0.010 |
Why?
|
| Chemokine CCL2 | 1 | 2000 | 12 | 0.010 |
Why?
|
| Pyridines | 1 | 2000 | 24 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2000 | 21 | 0.010 |
Why?
|
| Hypokalemia | 1 | 1980 | 7 | 0.010 |
Why?
|
| Syndrome | 1 | 1980 | 32 | 0.010 |
Why?
|
| Membrane Potentials | 2 | 1993 | 14 | 0.010 |
Why?
|
| Gastrins | 3 | 1983 | 4 | 0.010 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1998 | 1 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 1998 | 2 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1998 | 8 | 0.010 |
Why?
|
| Indazoles | 1 | 1997 | 3 | 0.010 |
Why?
|
| Lactones | 1 | 1996 | 1 | 0.010 |
Why?
|
| Ginkgolides | 1 | 1996 | 1 | 0.010 |
Why?
|
| Opossums | 1 | 1996 | 1 | 0.010 |
Why?
|
| Ligation | 1 | 1996 | 14 | 0.010 |
Why?
|
| Econazole | 1 | 1995 | 1 | 0.010 |
Why?
|
| Microvilli | 1 | 1991 | 1 | 0.010 |
Why?
|
| Absorption | 1 | 1991 | 5 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1991 | 2 | 0.010 |
Why?
|
| Cycloheximide | 1 | 1991 | 5 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 1991 | 44 | 0.010 |
Why?
|
| Ammonium Chloride | 1 | 1989 | 1 | 0.000 |
Why?
|
| 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid | 1 | 1989 | 1 | 0.000 |
Why?
|
| 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 1989 | 1 | 0.000 |
Why?
|
| Amiloride | 1 | 1989 | 2 | 0.000 |
Why?
|
| Acetic Acid | 1 | 1989 | 4 | 0.000 |
Why?
|
| Taurodeoxycholic Acid | 1 | 1989 | 1 | 0.000 |
Why?
|
| Translocation, Genetic | 1 | 1988 | 1 | 0.000 |
Why?
|
| Intracellular Fluid | 1 | 1988 | 3 | 0.000 |
Why?
|
| Stimulation, Chemical | 1 | 1988 | 15 | 0.000 |
Why?
|
| Aminopyrine | 1 | 1986 | 1 | 0.000 |
Why?
|
| Pepsin A | 1 | 1986 | 1 | 0.000 |
Why?
|
| Nifedipine | 1 | 1986 | 3 | 0.000 |
Why?
|
| Cesium | 1 | 1985 | 1 | 0.000 |
Why?
|
| Furosemide | 1 | 1985 | 1 | 0.000 |
Why?
|
| Rubidium | 1 | 1985 | 1 | 0.000 |
Why?
|
| Tetraethylammonium Compounds | 1 | 1985 | 1 | 0.000 |
Why?
|
| Tetraethylammonium | 1 | 1985 | 1 | 0.000 |
Why?
|
| Gynecomastia | 1 | 1983 | 1 | 0.000 |
Why?
|
| Gastric Acidity Determination | 1 | 1983 | 1 | 0.000 |
Why?
|
| Propantheline | 1 | 1983 | 1 | 0.000 |
Why?
|
| Prostaglandins E, Synthetic | 1 | 1983 | 1 | 0.000 |
Why?
|
| Histamine H2 Antagonists | 1 | 1983 | 2 | 0.000 |
Why?
|
| Parasympatholytics | 1 | 1983 | 4 | 0.000 |
Why?
|
| Angiography | 1 | 1983 | 15 | 0.000 |
Why?
|
| Ultrasonography | 1 | 1983 | 38 | 0.000 |
Why?
|
| Esophagogastric Junction | 1 | 1981 | 1 | 0.000 |
Why?
|
| Heartburn | 1 | 1981 | 1 | 0.000 |
Why?
|
| Manometry | 1 | 1981 | 1 | 0.000 |
Why?
|
| Esophagoscopy | 1 | 1981 | 4 | 0.000 |
Why?
|